Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective— Bexarotene (Targretin) is a clinically used antitumoral agent which exerts its action through binding to and activation of the retinoid-X-receptor (RXR). The most frequent side-effect of bexarotene administration is an increase in plasma triglycerides, an independent risk factor of cardiovascular disease. The molecular mechanism behind this hypertriglyceridemia remains poorly understood. Methods and Results— Using wild-type and LXRα/β-deficient mice, we show here that bexarotene induces hypertriglyceridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a permissive effect on RXR/LXR heterodimers. Interestingly, RNA analysis and Chromatin Immunoprecipitation assays performed in the liver reveal that the in vivo permissive effect of bexarotene on the RXR/LXR heterodimer is restricted to lipogenic genes without modulation of genes controlling cholesterol homeostasis. Conclusion— These findings demonstrate that the hypertriglyceridemic action of bexarotene occurs via the RXR/LXR heterodimer and show that RXR heterodimers can act with a selective permissivity on target genes of specific metabolic pathways in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233
Sorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Metabolic Effects of Rexinoids: Tissue-Specific Regulation of Lipoprotein Lipase Activity
Davies, P. J. A., Berry, S. A., Shipley, G. L., Eckel, R. H., Hennuyer, N., Crombie, D. L., Ogilvie, K. M., Peinado-Onsurbe, J., Fievet, C., Leibowitz, M. D., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.2.170 · Cited by 89
Cited by
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
The retinoid X receptors and their ligands
Dawson, M. I., & Xia, Z. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.014 · Cited by 387
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
“This arises from RXR (retinoid X receptor)-mediated expression of genes implicated in lipogenesis through heterodimerization with another nuclear LXR (liver X receptor).(142) Mild to moderate hypercholesterolemia appears to be a class effect as well of janus kinase (JAK) inhibitors, as this was also seen in clinical t…”
BackgroundRetinoid X receptors: common heterodimerization partners with distinct functions
Lefebvre, P., Benomar, Y., & Staels, B. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.009 · Cited by 309
Self-citationNuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
Saeed, A., Dullaart, R., Schreuder, T., Blokzijl, H., & Faber, K. (2017) · Nutrients · doi:10.3390/nu10010029 · Cited by 227
“Though no specific data are available on the RA-mediated expression of those genes, it is likely that they are co-regulated with key genes in DNL as a result of RXR/LXR and RAR-mediated effects on ChREBP and SREBP-1c.”
BackgroundInfluentialThe challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
Fessler, M. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.010 · Cited by 173
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134
ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies
Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160467 · Cited by 116
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Metadata
- Authors
- Lalloyer, F., Pedersen, T. A., Gross, B., Lestavel, S., Yous, S., Vallez, E., Gustafsson, J.-A., Mandrup, S., Fiévet, C., Staels, B., & Tailleux, A.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2009-10
- Volume
- 29
- Issue
- 10
- Pages
- 1488-1495
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1967680216
- Cited by
- 73
- References
- 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.